New blood thinner may prevent clots in kidney patients
NCT ID NCT07404436
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with idiopathic membranous nephropathy, a kidney disease that raises clot risk. About 134 participants at high risk for clots but low risk for bleeding will receive either rivaroxaban or warfarin for 6 months. Researchers will compare how many people in each group develop clots or experience bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rivaroxaban
What this could lead to
If successful, this could offer a simpler, safer way to prevent dangerous blood clots in people with this kidney disease.
What could go wrong
This is a small, single-center trial, so results may not apply widely. Bleeding risks are a concern with any blood thinner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friedship Hospital
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact